SHIONOGI - Tivicay (Dolutegravir) US Approval Comes with an Encouraging Broad Label. Focus Shifts on Data from FLEMINGO Study and Approval of Trii FDC!
Tivicay (Dolutegravir) US Approval Comes with an Encouraging Broad Label. Focus Shifts on Data from FLEMINGO Study and Approval of Trii FDC!
ViiVhealthcare today announced US approval of Tivicay (Dolutegravir) - it is approved both for treatment naïve and treatment experienced HIV patients and also in INSTI (integrase strand transfer inhibitor) resistance patients (except in patients where INSTI-resistance is due to Q148 substitution plus two or more additional INSTI resistance substitution). This will allow Tivicay to initially grab the INSTI resistance patient pool and a share from treatment naïve patient pool (naïve patients stay on therapy longer). We forecast $750m peak sales for Tivicay in this segment. Recently launched Stribild (Gilead, in 2Q12 in treatment naïve patients) has attained sales of $191m in the 1H 2013.
Approval of ‘572 Trii (dolutegravir FDC with Epizicom) and Data from FLAMINGO Study Will Open the Doors of A Bigger Opportunity
ViiVhealthcare today announced US approval of Tivicay (Dolutegravir) - it is approved both for treatment naïve and treatment experienced HIV patients and also in INSTI (integrase strand transfer inhibitor) resistance patients (except in patients where INSTI-resistance is due to Q148 substitution plus two or more additional INSTI resistance substitution). This will allow Tivicay to initially grab the INSTI resistance patient pool and a share from treatment naïve patient pool (naïve patients stay on therapy longer). We forecast $750m peak sales for Tivicay in this segment. Recently launched Stribild (Gilead, in 2Q12 in treatment naïve patients) has attained sales of $191m in the 1H 2013.
Approval of ‘572 Trii (dolutegravir FDC with Epizicom) and Data from FLAMINGO Study Will Open the Doors of A Bigger Opportunity
